This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

RAF265

Novartis AG

Drug Names(s): CHIR-265

Description: RAF265 is a novel, orally bioavailable small molecule inhibitor of the Raf kinases, including mutant B-Raf (V600E), that also inhibits VEGFR-2. Preclinical data suggest that RAF265 has both direct anti-proliferative/pro-apoptotic activity on tumor cells as well as anti-angiogenic activity that targets the tumor blood supply.

Deal Structure: CHIR-265 was originally developed by Chiron.

Chiron and Novartis
In April 2006, Novartis announced that shareholders of Chiron Corporation voted to approve its acquisition of Chiron. Under the terms of the transaction, which closed on April 20, Novartis acquired all outstanding shares of Chiron that Novartis does not already own for USD 48 per share. The all-cash deal represents a total value of USD 5.4 billion.

Array and Novartis
In February 2015, Novartis agreed to divest all assets related to its BRAF and MEK inhibitor drugs, currently in development, to Array BioPharma to settle charges that Novartiss $16 billion acquisition of GlaxoSmithKlines portfolio of cancer-treatment drugs would likely be anticompetitive. Under the terms of the proposed consent agreement, Novartis is required to provide transitional services to Array BioPharma to ensure that development of the BRAF and MEK inhibitors continues uninterrupted and that competition in BRAF...See full deal structure in Biomedtracker

Partners: Array BioPharma, Inc.


RAF265 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug